Filtered By:
Therapy: Statin Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 179 results found since Jan 2013.

Estimating the potential impact of LDL-C lowering through SIRNA therapies on population health: A simulation study
Background and Aims: Inclisiran, an siRNA therapy, provides sustained reductions in LDL-C. Potential CV benefits of inclisiran, as an adjunct to statins, were evaluated through simulation.
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: K. Ray, L. Gunn, L.G. Conde, F. Raal, R.S. Wright, N. Gosselin, L. Leiter, W. Koenig, G. Schwartz, U. Landmesser Source Type: research

Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease: A Review of Current and Emerging Therapies
AbstractLipoprotein(a), or Lp(a), is structurally like low-density lipoprotein (LDL) but differs in that it contains glycoprotein apolipoprotein(a) [apo(a)]. Due to its prothrombotic and proinflammatory properties, Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis. Lp(a) levels are genetically determined, and it is estimated that 20-25% of the global population has an Lp(a) level ≥50 mg/dL (or ≥125 nmol/L). Diet and lifestyle interventions have little to no effect on Lp(a) levels. Lipoprotein apheresis is the only approved treatment for elevated Lp(a) but i...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 19, 2023 Category: Drugs & Pharmacology Authors: Ibrahim S. Alhomoud, Azita Talasaz, Anurag Mehta, Michael Kelly, Evan M. Sisson, John D. Bucheit, Roy Brown, Dave L. Dixon Tags: REVIEW Source Type: research

Simvastatin prevents BMP-2 driven cell migration and invasion by suppressing oncogenic DNMT1 expression in breast cancer cells
This study emphasized to decipher the molecular mechanism of endogenous regulation of DNMT1 expression for finding upstream signaling molecules. Cancer database analyses found an upregulated DNMT1 expression in most cancer types including breast cancer. Overexpression of DNMT1 showed an increased cell migration, invasion, and stemness potential whereas 5-azacytidine (DNMT1 inhibitor) and siRNA mediated knockdown of DNMT1 exhibited inhibition of such cancer activities in breast cancer MDA-MB-231 and MCF-7 cells. Infact, cancer database analyses further found a positive correlation of DNMT1 transcript with both cholesterol p...
Source: Gene - July 13, 2023 Category: Genetics & Stem Cells Authors: Pooja Yadav Shreetama Bandyopadhayaya Sneha Soni Sunil Saini Lokendra K Sharma Sandeep K Shrivastava Chandi C Manda Source Type: research

High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany
CONCLUSION: In this real-world patient population referred to German lipid clinics for elevated LDL-C levels, inclisiran demonstrated a high interindividual variability in LDL-C reductions. Further research is warranted to elucidate reasons for the interindividual variability in drug efficacy.PMID:37422840 | DOI:10.1007/s00392-023-02247-8
Source: Clin Med Res - July 9, 2023 Category: Research Authors: U Makhmudova U Schatz N Perakakis U Kassner F Schumann C Axthelm P St ürzebecher D L Sinning A Doevelaar B Rohn T Westhoff A Vogt M Scholl U K ästner J-A Geiling K Stach J Mensch E Lorenz C Paitazoglou I Eitel A Baessler E Steinhagen-Thiessen W Koenig P Source Type: research

Lipoprotein(a) Lowering Medications - Another Step Forward in Atherosclerosis Management
J Cardiovasc Pharmacol. 2023 May 16. doi: 10.1097/FJC.0000000000001438. Online ahead of print.ABSTRACTASO and siRNA agents targeting Lp(a) appear to be promising treatment options for patients with elevated Lp(a) in addition to the classical therapies with statins or other cholesterol lowering drugs.PMID:37192439 | DOI:10.1097/FJC.0000000000001438
Source: Atherosclerosis - May 16, 2023 Category: Cardiology Authors: Boris B Boyanovsky Source Type: research

Inclisiran: A Review in Hypercholesterolemia
AbstractInclisiran (Leqvio®) is a first-in-class, subcutaneously administered, small interfering RNA (siRNA) that prevents hepatic synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), thereby decreasing circulating low-density lipoprotein cholesterol (LDL-C). In the EU, inclisiran is indicated in adults with primary hypercholesterolemia or mixed dyslipidemia, as an adjunct to diet. It is intended for use in patients unable to reach LDL-C goals on maximally tolerated statin therapy, with or without other lipid-lowering therapies (LLTs). In patients who are statin intolerant or for whom a statin is contraindi...
Source: American Journal of Cardiovascular Drugs - March 4, 2023 Category: Cardiology Source Type: research

Inclisiran-Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Pharmaceutics. 2023 Jan 18;15(2):323. doi: 10.3390/pharmaceutics15020323.ABSTRACTDyslipidemia is listed among important cardiovascular disease risk factors. Treating lipid disorders is difficult, and achieving desirable levels of LDL-cholesterol (LDL-C) is essential in both the secondary and primary prevention of cardiovascular disease. For many years, statins became the basis of lipid-lowering therapy. Nevertheless, these drugs are often insufficient due to their side effects and restrictive criteria for achieving the recommended LDL-C values. Even the addition of other drugs, i.e., ezetimibe, does not help one achieve th...
Source: Atherosclerosis - February 25, 2023 Category: Cardiology Authors: Łukasz Wołowiec Joanna Osiak Anna Wo łowiec Aleksandra Wijata El żbieta Grześk Mariusz Kozakiewicz Joanna Banach Alicja Nowaczyk Jacek Nowaczyk Grzegorz Grze śk Source Type: research

Current and future options in cholesterol lowering treatments
Eur J Intern Med. 2023 Feb 20:S0953-6205(23)00050-X. doi: 10.1016/j.ejim.2023.02.010. Online ahead of print.ABSTRACTThe relative risk reduction of cardiovascular events is proportional to the absolute reduction in LDL-C levels, the primary target of therapy, no matter the way of reduction. During the last decades, the therapeutic regimens for reducing the LDL-C levels have been immerged and improved, with favorable effects on the atherosclerotic process and clinical benefits of various cardiovascular outcomes. From a practical view of point, this review is focusing only on the current available lipid lowering agents: stati...
Source: European Journal of Internal Medicine - February 22, 2023 Category: Internal Medicine Authors: Avishay Elis Source Type: research